Alpha-GPC (L-alpha-glycerylphosphorylcholine / choline alfoscerate) vs Oxiracetam

N/A

N/A

Published human studies used 400–600 mg/day for 2–12 weeks (cognitive/motivation trials) and single acute 600 mg doses (exercise study); the classic prescription dose (choline alfoscerate) in some markets is 1200 mg/day. These are reported as trial/regulatory facts, not recommendations. Alpha-GPC is a non-peptide small molecule sold as bulk powder or capsules at marketed purities of 50%, 99%, or 99.96%. No validated maximum safe dose, no controlled long-term safety data beyond 12 weeks, and no pediatric or pregnancy safety data were located.

Historical European trials used 400–2400 mg/day (escalating) or 800 mg twice daily under physician supervision as trial protocols, not general safety guidance. In elderly patients given a single 800 mg oral dose, peak serum was ~25±6 µg/mL at 1–3 hours, elimination half-life 3–6 hours, with ~84% recovered unchanged in urine within 24 hours and no accumulation over 7 days of 800 mg twice daily. Drug clearance is reduced in the elderly (AUC approximately doubled versus younger subjects) due to age-related renal decline; renal impairment materially affects elimination. Product identity and purity cannot be assumed from vendor listings; a peer-reviewed 2021 supplement study found oxiracetam claimed on labels but absent from tested products, warranting third-party lab verification.